SUWANEE, GA / ACCESSWIRE / December 20, 2016 / SANUWAVE Health, Inc. (OTCQB: SNWV) today reported positive business developments
leading to a strong outlook for its fourth quarter ending December 31, 2016 and its first quarter ending March 31, 2017.
"Our renewed focus on international sales distributors during 2016 have positioned SANUWAVE for a strong fourth quarter and a
breakthrough 2016 with revenue exceeding $1M, the highest level as a public company," noted Kevin A. Richardson, II, Chairman of
the Board of SANUWAVE Health. "We more than doubled the number of units shipped in 2016. This should lead to stronger refurbishment
business in 2017 and beyond. We laid the groundwork for the addition of new countries and partners in 2017, which will continue our
strong order growth into 2017. We also continue to work towards our near-term goals of FDA approval for dermaPACE®."
-
Accelerating Sales and Order Backlog: The Company expects to post revenues of $450,000 to $650,000 in the fourth quarter of 2016,
up 21% to 75% from the prior year period. Orders received to date are expected to be strong for the first quarter of 2017. - Patent
Portfolio Continues To Grow: In 2016, SANUWAVE has been awarded 4 patents and filed 2 new patent applications, bringing the
portfolio of issued patents and applications up to 58. The patents issued in 2016 provide protection on new device design elements
(electrodes, reflectors, and applicator's construction), in order to improve functionality and efficiency of our proprietary
acoustic pressure shock wave technology in both medical and non-medical fields.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and
commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin,
musculoskeletal tissue, and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates
activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps
restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®,
is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in
Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for
the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and
believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot
(plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as
stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron,
Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for
SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, such as statements relating to financial results and plans for future business development activities, and are thus
prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief
or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's
ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key
risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the
regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development
activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors
discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no
obligation to update any forward-looking statement.
For additional information about the Company, visit www.sanuwave.com.
Contact:
Millennium Park Capital LLC Christopher Wynne 312-724-7845 cwynne@mparkcm.com
SANUWAVE Health, Inc. Kevin Richardson II Chairman of the Board 978-922-2447 investorrelations@sanuwave.com
SOURCE: SANUWAVE Health, Inc.
